Effect of vinpocetine alone and in combination with enalapril in experimental model of diabetic cardiomyopathy in rats : possible involvement of PDE-1/TGF-β/ Smad 2/3 signalling pathways
© The Author(s) 2023. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVE: Diabetic cardiomyopathy (DC) is one of the severe secondary complications of diabetes mellitus in humans. Vinpocetine is an alkaloid having pleiotropic pharmacological effects. The present study is designed to investigate the effect of vinpocetine in DC in rats.
METHODS: Rats were fed a high-fat diet for nine weeks along with single dose of streptozotocin after the second week to induce DC. The haemodynamic evaluation was performed to assess the functional status of rats using the Biopac system. Cardiac echocardiography, biochemical, oxidative stress parameters and inflammatory cytokine level were analysed in addition to haematoxylin-eosin and Masson's trichome staining to study histological changes, cardiomyocyte diameter and fibrosis, respectively. Phosphodiesterase-1 (PDE-1), transforming growth factor-β (TGF-β) and p-Smad 2/3 expression in cardiac tissues were quantified using western blot/RT-PCR.
KEY FINDING: Vinpocetine treatment and its combination with enalapril decreased the glucose levels compared to diabetic rats. Vinpocetine improved the echocardiographic parameters and cardiac functional status of rats. Vinpocetine decreased the cardiac biochemical parameters, oxidative stress, inflammatory cytokine levels, cardiomyocyte diameter and fibrosis in rats. Interestingly, expressions of PDE-1, TGF-β and p-Smad 2/3 were ameliorated by vinpocetine alone and in combination with enalapril.
CONCLUSIONS: Vinpocetine is a well-known inhibitor of PDE-1 and the protective effect of vinpocetine in DC is exerted by inhibition of PDE-1 and subsequent inhibition of the expression of TGF-β/Smad 2/3.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
The Journal of pharmacy and pharmacology - 75(2023), 9 vom: 01. Sept., Seite 1198-1211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vishwakarma, Vishal Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
543512OBTC |
|---|
| Anmerkungen: |
Date Completed 05.09.2023 Date Revised 05.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jpp/rgad043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357319478 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357319478 | ||
| 003 | DE-627 | ||
| 005 | 20231226072331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jpp/rgad043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357319478 | ||
| 035 | |a (NLM)37229596 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vishwakarma, Vishal Kumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of vinpocetine alone and in combination with enalapril in experimental model of diabetic cardiomyopathy in rats |b possible involvement of PDE-1/TGF-β/ Smad 2/3 signalling pathways |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.09.2023 | ||
| 500 | |a Date Revised 05.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVE: Diabetic cardiomyopathy (DC) is one of the severe secondary complications of diabetes mellitus in humans. Vinpocetine is an alkaloid having pleiotropic pharmacological effects. The present study is designed to investigate the effect of vinpocetine in DC in rats | ||
| 520 | |a METHODS: Rats were fed a high-fat diet for nine weeks along with single dose of streptozotocin after the second week to induce DC. The haemodynamic evaluation was performed to assess the functional status of rats using the Biopac system. Cardiac echocardiography, biochemical, oxidative stress parameters and inflammatory cytokine level were analysed in addition to haematoxylin-eosin and Masson's trichome staining to study histological changes, cardiomyocyte diameter and fibrosis, respectively. Phosphodiesterase-1 (PDE-1), transforming growth factor-β (TGF-β) and p-Smad 2/3 expression in cardiac tissues were quantified using western blot/RT-PCR | ||
| 520 | |a KEY FINDING: Vinpocetine treatment and its combination with enalapril decreased the glucose levels compared to diabetic rats. Vinpocetine improved the echocardiographic parameters and cardiac functional status of rats. Vinpocetine decreased the cardiac biochemical parameters, oxidative stress, inflammatory cytokine levels, cardiomyocyte diameter and fibrosis in rats. Interestingly, expressions of PDE-1, TGF-β and p-Smad 2/3 were ameliorated by vinpocetine alone and in combination with enalapril | ||
| 520 | |a CONCLUSIONS: Vinpocetine is a well-known inhibitor of PDE-1 and the protective effect of vinpocetine in DC is exerted by inhibition of PDE-1 and subsequent inhibition of the expression of TGF-β/Smad 2/3 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a TGF-β | |
| 650 | 4 | |a diabetic cardiomyopathy | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a phosphodiesterase-1 | |
| 650 | 4 | |a vinpocetine | |
| 650 | 7 | |a Enalapril |2 NLM | |
| 650 | 7 | |a 69PN84IO1A |2 NLM | |
| 650 | 7 | |a Phosphoric Diester Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.1.4.- |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta |2 NLM | |
| 650 | 7 | |a vinpocetine |2 NLM | |
| 650 | 7 | |a 543512OBTC |2 NLM | |
| 700 | 1 | |a Shah, Sadia |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Tajpreet |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Amrit Pal |e verfasserin |4 aut | |
| 700 | 1 | |a Arava, Sudheer Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Niraj |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Raj Kanwar |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Sushma |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Taruna |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Harlokesh Narayan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of pharmacy and pharmacology |d 1949 |g 75(2023), 9 vom: 01. Sept., Seite 1198-1211 |w (DE-627)NLM000019046 |x 2042-7158 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:1198-1211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jpp/rgad043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |e 9 |b 01 |c 09 |h 1198-1211 | ||